BofA raised the firm’s price target on Genmab (GMAB) to $38.50 from $34.70 and keeps a Buy rating on the shares. The company last week outlined a “catalyst rich” fiscal 2026, the analyst tells investors in a research note. The firm is “bullish” into Genmab’s three major catalysts in 2026, seeing each offering a $2B peak sales opportunity in attractive markets.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Maintaining Buy on Genmab: Epkinly Combination Potential Outweighs Monotherapy Setback
- Genmab: Limited Epkinly Approval Risk and High-Value 2026 Pipeline Catalysts Support Buy Rating
- Truist maintains optimism for 2026 read-out after Genmab’s Phase 3 trial OS miss
- Genmab Reports Positive Phase 3 Progression-Free Survival Data for Epcoritamab in Relapsed/Refractory DLBCL
- AbbVie announces results for epcoritamab from Phase 3 EPCORE DLBCL-1 trial